Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and ε-aminocaproic acid — a meta-analysis of randomised and observational trials of over 30.000 patients.

This content is restricted to subscribers. If you are already a subscriber, please log in.